NCT01125800 - A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

MedulloblastomaRhabdomyosarcomaNeuroblastomaHepatoblastomaGliomaAstrocytoma

Interventions

DRUG

LDE225

LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.

Trial Locations (14)

Novartis Investigative Site, Parkville

Novartis Investigative Site, Milan

Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins, Baltimore

Children's Healthcare of Atlanta Childern Hosp - ATL, Atlanta

Novartis Investigative Site, Bologna

Novartis Investigative Site, Paris

Novartis Investigative Site, Villejuif

Seattle Children's Hospital CPKC412A2114, Seattle

Dana Farber Cancer Institute DFCI (3), Boston

Novartis Investigative Site, Toronto

Novartis Investigative Site, Toronto

Novartis Investigative Site, Roma

Novartis Investigative Site, Sutton

Novartis Investigative Site, Newcastle upon Tyne